Clinical trials: Enoxaparin, completed
Deep Venous Thrombosis, Pulmonary Embolism
Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE).
- Trial name
- Highlow (NCT01828697)
- Testing
- Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 1,110 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Venous Thrombosis, Neoplasms
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible.
- Trial name
- NCT01999179
- Testing
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Medical College of Wisconsin
COVID-19 Pandemic
Safety and Efficacy of Enoxaparin and Hydroxychloroquine in COVID-19
In this randomized controlled study, two hundred patients with positive PCR and laboratory confirmed COVID-19 will be classified randomly into four groups.
- Trial name
- NCT05311813
- Testing
- Enoxaparin, Hydroxychloroquine
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Beni-Suef University
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Acute Coronary Syndrome, Myocardial Infarction
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
H-REPLACE trial is a prospective, randomized, open-label, active-controlled, multicenter study in participants with ACS (STEMI or NSTEMI, unstable angina).
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- H-REPLACE (NCT03363035)
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Enoxaparin
- Where
- 24 sites in China
- Volunteers
- 2,055 people
- Sponsor
- Second Xiangya Hospital of Central South University
Dose Adjustment of Enoxaparin in ICU Patients
Anti-factor Xa Based Venous Thromboembolism Prophylaxis
Introduction: Venous thromboembolism (VTE) in the intensive care unit (ICU) is associated with significant morbidity and mortality therefore prevention is imperative to reduce its burden.
- Trial name
- NCT05221879
- Testing
- Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Meir Medical Center
Thromboembolism, Postpartum DVT
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
The aim of this study is to evaluate the efficacy of two dosing regimens of low molecular weight heparin (LMWH) to reach prophylactic anti-factor Xa levels in post-cesarean delivery women.
- Conditions
- Thromboembolism, Postpartum DVT, Thrombosis
- Trial name
- NCT04305756
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Utah
COVID-19, Venous Thromboembolism
Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
Study purpose was to study the safety and efficacy of Dimolegin - DD217 as a drug for prevention of thrombotic complications compared to Clexane (enoxaparin sodium) - the standard therapy currently prescribed to patients…
- Trial name
- NCT05185804
- Testing
- Dimolegin, Clexane
- Where
- 6 sites in Russia
- Volunteers
- 399 people
- Sponsor
- PharmaDiall Ltd.
Venous Thromboembolism, Pulmonary Embolism
A Different Approach to Preventing Thrombosis
The purpose of this study is to perform a pragmatic randomized controlled trial to compare the use of low molecular weight heparin (LMWH, lovenox, enoxaparin) versus acetylsalicylic acid (ASA) for venous thromboembolism (VTE)…
- Trial name
- ADAPT (NCT02774265)
- Testing
- VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- University of Maryland, Baltimore
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Traumatic Injury, Venous Thromboembolism
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE…
- Trial name
- NCT02412982
- Testing
- Enoxaparin 40 mg q12h, Enoxaparin 30 mg q8h
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Cincinnati
Covid19
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients with COVID-19.
- Trial name
- INSPIRATION (NCT04486508)
- Testing
- intermediate dose Enoxaparin/ unfractionated heparin, standard prophylactic dose Enoxaparin/ unfractionated heparin, Atorvastatin 20mg
- Where
- Iran
- Volunteers
- 600 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with 40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin using soft mist inhaler in the treatment of…
- Trial name
- NCT04990830
- Testing
- Inhaled Low molecular weight heparin, Standard Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Istanbul University
Gastrointestinal Neoplasms, Thromboembolic Event
Comparison of Thromboembolic Events in Patients Undergoing Thromboprophylactic Treatment With ENOXA® vs Lovenox®
Prospective, monocentric, randomized, parallel group, rater-blinded study using two formulations of Enoxaparin sodium (ENOXA® vs LOVENOX®) to compare the thromboembolic events (symptomatic and asymptomatic) in patients undergoing…
- Trial name
- ENOXACARE (NCT02444572)
- Testing
- Enoxaparin 4000 IU
- Where
- Tunisia
- Volunteers
- 168 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Venous Thormboembolism
Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
Hospitalized patients with histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma, or multiple myeloma and who are at high risk for a venous thromboembolism will be randomized to standard dose…
- Trial name
- NCT02706249
- Testing
- Enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
Coronavirus Infection
Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial
Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer.
- Trial name
- ACTION (NCT04394377)
- Testing
- Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed, Group 2: control group with enoxaparin 40mg/d
- Where
- 36 sites in Brazil
- Volunteers
- 615 people
- Sponsor
- Brazilian Clinical Research Institute
Covid19
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in…
- Trial name
- X-Covid 19 (NCT04366960)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 189 people
- Sponsor
- Niguarda Hospital
Thrombophilia Associated With Pregnancy, Perioperative/Postoperative Complications
Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial
Hospitalization in pregnancy and childbirth greatly increases the thromboembolic risk of these patients. The application of a protocol for assessing the risk of VTE reduces mortality and morbidity of these phenomena.
- Conditions
- Thrombophilia Associated With Pregnancy, Perioperative/Postoperative Complications, Venous Thrombosis, Pulmonary Embolism
- Trial name
- NCT02600260
- Testing
- Enoxaparin, No intervention
- Where
- Brazil
- Volunteers
- 7,212 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Venous Thromboembolism, Traumatic Brain Injury
Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
Brain injured patients are at high risk for forming blood clots in the legs and lungs. For non-brain injured trauma patients, we decrease the chances of these blood clots forming by placing the patients on a low dose of the blood…
- Trial name
- DEEP (NCT01014403)
- Testing
- enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Texas Southwestern Medical Center